| Literature DB >> 35665130 |
Chen-Ke Pan1, Bo-Wen Zhao2, Xuan-Xuan Zhang3, Mei Pan1, Yan-Kai Mao1, Yuan Yang1.
Abstract
BACKGROUND: HeartModel (HM) is a fully automated adaptive quantification software that can quickly quantify left heart volume and left ventricular function. This study used HM to quantify the left ventricular end-diastolic (LVEDV) and end-systolic volumes (LVESV) of patients with dilated cardiomyopathy (DCM), coronary artery heart disease with segmental wall motion abnormality, and hypertrophic cardiomyopathy (HCM) to determine whether there were differences in the feasibility, accuracy, and repeatability of measuring the LVEDV, LVESV, LV ejection fraction (LVEF) and left atrial end-systolic volume (LAESV) and to compare these measurements with those obtained with traditional two-dimensional (2D) and three-dimensional (3D) methods. AIM: To evaluate the application value of HM in quantifying left heart chamber volume and LVEF in clinical patients.Entities:
Keywords: HeartModel; Left atrial volume; Left ventricular ejection function; Left ventricular volume; Three-dimensional echocardiography
Year: 2022 PMID: 35665130 PMCID: PMC9131239 DOI: 10.12998/wjcc.v10.i13.4050
Source DB: PubMed Journal: World J Clin Cases ISSN: 2307-8960 Impact factor: 1.534
Figure 1HeartModel algorithm. The HeartModel algorithm automatically detects three-dimensional end-diastolic and end-systolic endocardial contours of the left ventricle and the left atrium with possibility of further manual adjustments if needed. Right chamber contours are also delineated; however, numerical results are not provided in the current version of the software.
Comparison of left ventricular volume and left ventricular ejection fraction measured by the different transthoracic echocardiographic methods in 4 groups (mean ± SD)
|
|
|
|
|
|
|
|
| Group A (control group, | ||||||
| LVEDV (mL) | 77.5 ± 13.7 | 82.5 ± 11.6 | 70.6 ± 10.9 | 77.1 ± 15.4 | 91.0 ± 17.5 | 86.3 ± 15.9 |
| LVESV (mL) | 25.7 ± 5.3 | 27.5 ± 4.9 | 24.2 ± 4.5 | 26.3 ± 6.7 | 31.5 ± 6.9 | 29.6 ± 6.4 |
| LVEF (%) | 66.6 ± 4.3 | 66.5 ± 4.2 | 65.6 ± 3.4 | 65.8 ± 4.0 | 65.2 ± 4.2 | 65.5 ± 3.9 |
| LAESV (mL) | 36.8 ± 9.6 | NS | 35.2 ± 9.9 | NS | 41.2 ± 10.5 | 39.8 ± 10.6 |
| Group B (DCM, | ||||||
| LVEDV (mL) | 147.4 ± 34.7 | 205.7 ± 52.7 | 162.7 ± 46.6 | 154.3 ± 38.0 | 187.5 ± 52.3 | 186.1 ± 45.8 |
| LVESV (mL) | 96.6 ± 30.0 | 132.4 ± 40.4 | 103.1 ± 36.1 | 99.7 ± 32.3 | 115.6 ± 39.0 | 119.6 ± 40.4 |
| LVEF (%) | 35.1 ± 9.5 | 36.2 ± 7.9 | 37.3 ± 8.8 | 35.9 ± 9.3 | 37.9 ± 11.1 | 35.9 ± 9.4 |
| LAESV (mL) | 60.4 ± 26.5 | NS | 62.9 ± 33.0 | NS | 68.0 ± 34.6 | 69.4 ± 33.1 |
| Group C (SWMA, | ||||||
| LVEDV (mL) | 121.4 ± 50.8 | 183.8 ± 73.1 | 135.1 ± 51.7 | 124.7 ± 51.9 | 170.3 ± 57.7 | 162.5 ± 56.9 |
| LVESV (mL) | 74.2 ± 35.6 | 111.6 ± 56.4 | 79.6 ± 37.2 | 75.4 ± 35.3 | 94.5 ± 40.4 | 95.5 ± 40.2 |
| LVEF (%) | 40.0 ± 10.2 | 41.5 ± 10.1 | 42.4 ± 10.2 | 40.6 ± 8.4 | 45.3 ± 11.8 | 42.5 ± 8.6 |
| LAESV (mL) | 73.2 ± 51.0 | NS | 74.4 ± 53.5 | NS | 84.9 ± 57.4 | 82.4 ± 57.8 |
| Group D (HCM, | ||||||
| LVEDV (mL) | 80.0 ± 21.5 | 104.8 ± 32.2 | 75.7 ± 21.6 | 80.6 ± 22.4 | 112.6 ± 27.1 | 105.6 ± 31.6 |
| LVESV (mL) | 27.8 ± 8.7 | 32.3 ± 12.3 | 24.7 ± 9.5 | 28.3 ± 9.5 | 47.1 ± 14.8 | 40.1 ± 14.0 |
| LVEF (%) | 65.1 ± 5.6 | 69.4 ± 6.4 | 67.6 ± 7.1 | 65.0 ± 5.7 | 58.3 ± 7.5 | 62.1 ± 5.6 |
| LAESV (mL) | 70.4 ± 30.5 | NS | 71.5 ± 38.5 | NS | 89.3 ± 45.3 | 83.1 ± 42.1 |
P < 0.05 is statistically significant.
NS: Not significant; 3DQA: Advanced cardiac three-dimensional quantification; 3DQ: Cardiac three-dimensional quantification; HM-NE: HeartModel without regional endocardial border editing; HM-RE: HeartModel with regional endocardial border editing; LVEDV: Left ventricular end-diastolic volume; LVESV: Left ventricular end-systolic volume; LVEF: Left ventricular ejection fraction; LAESV: Left atrial end-systolic volume; DCM: Dilated cardiomyopathy; SWMA: Segmental wall motion abnormality; HCM: Hypertrophic cardiomyopathy.
Comparison of left ventricular volume and left ventricular ejection fraction measured by HeartModel with and without regional endocardial border editing (mean ± SD)
|
|
|
| ||||||
|
|
|
|
|
|
|
|
| |
| Group A | 91.0 ± 17.5 | 31.5 ± 6.9 | 65.2 ± 4.2 | 41.2 ± 10.5 | 86.3 ± 15.9 | 29.6 ± 6.4 | 65.5 ± 3.9 | 39.8 ± 10.6 |
| Group B | 187.5 ± 52.3 | 115.6 ± 39.0 | 37.9 ± 11.1 | 68.0 ± 34.6 | 186.1 ± 45.8 | 119.6 ± 40.4 | 35.9 ± 9.4 | 69.4 ± 33.1 |
| Group C | 170.3 ± 57.7 | 94.5 ± 40.4 | 45.3 ± 11.8 | 84.9 ± 57.4 | 162.5 ± 56.9 | 95.5 ± 40.2 | 42.5 ± 8.6 | 82.4 ± 57.8 |
| Group D | 112.6 ± 27.1 | 47.1 ± 14.8 | 58.3 ± 7.5 | 89.3 ± 45.3 | 105.6 ± 31.6 | 40.1 ± 14.0 | 62.1 ± 5.6 | 83.1 ± 42.1 |
P < 0.05.
HM-NE: HeartModel without regional endocardial border editing; HM-RE: HeartModel with regional endocardial border editing; LVEDV: Left ventricular end-diastolic volume; LVESV: Left ventricular end-systolic volume; LVEF: Left ventricular ejection fraction; LAESV: Left atrial end-systolic volume.
Figure 2Bland-Altman analysis for left heart volumes and ejection fraction between HeartModel with and without contour edit. A: Left ventricular end-diastolic volume; B: Left ventricular end-systolic volume; C: Left ventricular ejection fraction; D: Left atrial end-systolic volume. HM-NE: HeartModel without contour edit; HM-RE: HeartModel with contour edit; LVEDV: Left ventricular end-diastolic volume; LVESV: Left ventricular end-systolic volume; LVEF: Left ventricular ejection fraction; LAESV: Left atrial end-systolic volume.
Comparison of left ventricular volume and left ventricular ejection fraction measured by M-mode echocardiography, Biplane Simpson, and HeartModel methods against advanced cardiac three-dimensional quantification
|
|
|
|
|
|
| Teichholz ( | ||||
| LVEDV (mL) | 0.82 | 37.3 ± 82.7 | 35.1 | 66.1 |
| LVESV (mL) | 0.91 | 20.0 ± 56.2 | 35.8 | 85.2 |
| LVEF (%) | 0.89 | 1.5 ± 12.3 | 3.0 | 23.5 |
| Biplane Simpson ( | ||||
| LVEDV (mL) | 0.87 | 4.6 ± 46.8 | 4.3 | 43.0 |
| LVESV (mL) | 0.94 | 1.9 ± 26.9 | 3.4 | 47.2 |
| LVEF (%) | 0.91 | 1.4 ± 11.8 | 2.7 | 22.6 |
| LAESV (mL) | 0.93 | 0.7 ± 23.7 | 1.2 | 39.6 |
| 3DQ ( | ||||
| LVEDV (mL) | 0.96 | 2.4 ± 21.3 | 2.3 | 19.8 |
| LVESV (mL) | 0.98 | 1.3 ± 11.2 | 2.3 | 19.8 |
| LVEF (%) | 0.98 | 0.1 ± 5.2 | 0.2 | 10.1 |
| HM-NE ( | ||||
| LVEDV (mL) | 0.85 | 33.4 ± 56.4 | 31.4 | 45.8 |
| LVESV (mL) | 0.90 | 15.7 ± 33.0 | 28.0 | 51.6 |
| LVEF (%) | 0.85 | -0.2 ± 16.8 | -0.4 | -32.5 |
| LAESV (mL) | 0.93 | 10.2 ± 30.3 | 17.2 | 47.0 |
| HM-RE ( | ||||
| LVEDV (mL) | 0.91 | 28.1 ± 47.6 | 26.4 | 39.5 |
| LVESV (mL) | 0.93 | 14.92 ± 30.9 | 26.6 | 48.7 |
| LVEF (%) | 0.95 | -0.0 ± 9.8 | -0.0 | -19.0 |
| LAESV (mL) | 0.95 | 8.1 ± 23.7 | 13.7 | 37.4 |
Relative bias = (parametermethod-parameter 3DQA)/parametermethod; Percentage error = LOA/mean value of parameter measured by studied method and 3DQA. LOA: Limits of agreement; 3DQA: Advanced cardiac three-dimensional quantification; 3DQ: Cardiac three-dimensional quantification; HM-NE: HeartModel without regional endocardial border editing; HM-RE: HeartModel with regional endocardial border editing; LVEDV: Left ventricular end-diastolic volume; LVESV: Left ventricular end-systolic volume; LVEF: Left ventricular ejection fraction; LAESV: Left atrial end-systolic volume; DCM: Dilated cardiomyopathy; SWMA: Segmental wall motion abnormality; HCM: Hypertrophic cardiomyopathy.
Figure 3Correlation and Bland-Altman analysis for left heart volumes and ejection fraction between HeartModel without contour edit and advanced cardiac three-dimensional quantification. A and B: Left ventricular end-diastolic volume; C and D: Left ventricular end-systolic volume; E and F: Left ventricular ejection fraction; G and H: Left atrial end-systolic volume. HM-NE: HeartModel without contour edit; 3DQA: Advanced cardiac three-dimensional quantification; LVEDV: Left ventricular end-diastolic volume; LVESV: Left ventricular end-systolic volume; LVEF: Left ventricular ejection fraction; LAESV: Left atrial end-systolic volume.
Comparison of left ventricular volume and left ventricular ejection fraction measured by HeartModel with regional endocardial border editing and advanced cardiac three-dimensional quantification in 4 groups (mean ± SD)
|
|
|
|
|
|
|
|
| Group A (control group, | ||||||
| LVEDV (mL) | 86.3 ± 15.9a | 77.5 ± 13.7 | 0.82 | 8.8 ± 16.1 | 11.3 | 10.7 |
| LVESV (mL) | 29.6 ± 6.4 | 25.7 ± 5.3 | 0.85 | 3.8 ± 5.5 | 15.1 | 14.0 |
| LVEF (%) | 65.5 ± 3.9a | 66.6 ± 4.3 | 0.96 | -1.0 ± 2.4 | -1.5 | -1.5 |
| LAESV (mL) | 39.8 ± 10.6 | 36.8 ± 9.6 | 0.97 | 2.9 ± 3.9 | 8.1 | 7.7 |
| Group B (DCM, | ||||||
| LVEDV (mL) | 186.1 ± 45.8 | 147.4 ± 34.7 | 0.83 | 38.6 ± 45.7 | 26.2 | 23.1 |
| LVESV (mL) | 119.6 ± 40.4 | 96.6 ± 30.0 | 0.86 | 23.0 ± 39.6 | 23.8 | 21.3 |
| LVEF (%) | 35.9 ± 9.4 | 35.1 ± 9.5 | 0.71 | 0.7 ± 12.8 | 2.2 | 2.2 |
| LAESV (mL) | 69.4 ± 33.1 | 60.4 ± 26.5 | 0.92 | 7.5 ± 27.7 | 12.5 | 11.8 |
| Group C (SWMA, | ||||||
| LVEDV (mL) | 162.5 ± 56.9 | 121.4 ± 50.8 | 0.90 | 41.0 ± 46.7 | 33.8 | 28.9 |
| LVESV (mL) | 95.5 ± 40.2 | 74.2 ± 35.6 | 0.90 | 21.3 ± 31.0 | 28.7 | 25.1 |
| LVEF (%) | 42.5 ± 8.6 | 40.0 ± 10.2 | 0.80 | 2.5 ± 11.0 | 6.2 | 6.0 |
| LAESV (mL) | 82.4 ± 57.8 | 73.2 ± 51.0 | 0.89 | 9.2 ± 25.7 | 12.6 | 11.9 |
| Group D (HCM, | ||||||
| LVEDV (mL) | 105.6 ± 31.6 | 80.0 ± 21.5 | 0.54 | 25.5 ± 46.4 | 31.9 | 27.5 |
| LVESV (mL) | 40.1 ± 14.0 | 27.8 ± 8.7 | 0.48 | 12.3 ± 20.9 | 26.1 | 36.2 |
| LVEF (%) | 62.1 ± 5.6 | 65.1 ± 5.6 | 0.78 | -2.9 ± 6.5 | -5.0 | -4.6 |
| LAESV (mL) | 83.1 ± 42.1 | 70.4 ± 30.5 | 0.98 | 12.7 ± 31.1 | 18.1 | 16.6 |
P < 0.05.
Relative bias = (parametermethod-parameter 3DQA)/parametermethod; percentage error = LOA/mean value of parameter measured by studied method and 3DQA. 3DQA: Advanced cardiac three-dimensional quantification; LOA: Limits of agreement; HM-RE: HeartModel with regional endocardial border editing; LVEDV: Left ventricular end-diastolic volume; LVESV: Left ventricular end-systolic volume; LVEF: Left ventricular ejection fraction; LAESV: Left atrial end-systolic volume; DCM: Dilated cardiomyopathy; SWMA: Segmental wall motion abnormality; HCM: Hypertrophic cardiomyopathy.
Figure 4Correlation and Bland-Altman analysis for left heart volumes and ejection fraction between HeartModel with contour edit and advanced cardiac three-dimensional quantification. A and B: Left ventricular end-diastolic volume; C and D: Left ventricular end-systolic volume; E and F: Left ventricular ejection fraction; G and H: Left atrial end-systolic volume. HM-RE: HeartModel with contour edit; 3DQA: Advanced cardiac three-dimensional quantification; LVEDV: Left ventricular end-diastolic volume; LVESV: Left ventricular end-systolic volume; LVEF: Left ventricular ejection fraction; LAESV: Left atrial end-systolic volume.
Intraobserver, and interobserver variability (coefficient of variation) for the HeartModel with regional endocardial border editing in 4 Groups (mean ± SD)
|
|
|
| ||||||
|
|
|
|
|
|
|
|
| |
| Group A | 6.6 ± 5.6 | 11.1 ± 10.4 | 4.2 ± 3.8 | 5.8 ± 5.5 | 6.7 ± 3.8 | 11.3 ± 7.4 | 4.2 ± 2.1 | 7.2 ± 6.0 |
| Group B | 6.6 ± 5.1 | 10.2 ± 4.9 | 8.4 ± 9.4 | 8.4 ± 5.1 | 7.8 ± 3.2 | 10.4 ± 5.2 | 8.7 ± 6.3 | 8.5 ± 4.8 |
| Group C | 9.1 ± 7.5 | 10.2 ± 7.3 | 7.9 ± 11.9 | 7.2 ± 7.3 | 9.4 ± 5.8 | 10.2 ± 7.1 | 8.2 ± 6.2 | 8.1 ± 6.0 |
| Group D | 10.3 ± 4.6 | 14.9 ± 5.2 | 7.1 ± 1.7 | 7.5 ± 5.7 | 17.1 ± 7.6 | 20.1 ± 7.4 | 7.8 ± 5.1 | 7.7 ± 5.1 |
LVEDV: Left ventricular end-diastolic volume; LVESV: Left ventricular end-systolic volume; LVEF: Left ventricular ejection fraction; LAESV: Left atrial end-systolic volume.